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Prediction of ESRD in Pauci-immune Necrotizing Glomerulonephritis:
Quantitative Histomorphometric Assessment and Serum Creatinine
Clara J. Day, BMBCh, PhD,1 Alec J. Howie, MD,2 Peter Nightingale, PhD,3
Shazia Shabir, MBChB,1 Dwomoa Adu, MD,1 Caroline O. Savage, FMedSci,4 and
Peter Hewins, MBChB, PhD1,4
Background: Clinical and pathologic features that predict outcome have important potential applica-
tion in patients with pauci-immune necrotizing glomerulonephritis (usually antineutrophil cytoplasmic
antibody–associated vasculitis). This study examines the predictive value of simple quantitative renal
histologic measurements in a large cohort with extended follow-up.
Study Design: Cohort study.
Setting & Participants: 390 consecutive patients with pauci-immune necrotizing glomerulonephritis
at a single hospital (1983-2002); 90 patients underwent repeated kidney biopsy during follow-up.
Predictors: Age and serum creatinine concentration at biopsy, antineutrophil cytoplasmic antibody specificity,
percentage of normal glomeruli, percentage of glomeruli with active lesions, and index of chronic damage
(quantitative measurement of established cortical damage) in the initial kidney biopsy for all patients. The same
factors were assessed in both biopsy specimens for patients undergoing an additional biopsy.
Outcomes & Measurements: End-stage renal disease and patient survival.
Results: Mortality at 1 and 5 years was 23% and 40%, respectively: standardized mortality ratio, 4.74
(95% CI, 3.62-6.32). End-stage renal disease was reached by 14% and 18% at 1 and 5 years,
respectively. In multivariable analysis, serum creatinine level at biopsy and percentage of normal
glomeruli in the initial biopsy specimen were the best predictors of kidney survival. C Statistics were 0.80
for creatinine level alone and 0.83 for creatinine level with normal glomeruli. In patients undergoing an
additional biopsy, rapid progression in the index of chronic damage and serum creatinine level at the
second biopsy were associated with kidney survival in multivariable analysis.
Limitations: Retrospective analysis. External validity of the index of chronic damage requires further
assessment. Selection bias may influence repeated biopsy analyses.
Conclusions: Serum creatinine level at biopsy best predicts kidney survival in patients with
pauci-immune necrotizing glomerulonephritis overall.
Am J Kidney Dis 55:250-258. Crown Copyright © 2010 Published by Elsevier Inc. on behalf of the
National Kidney Foundation, Inc. All rights reserved.
INDEX WORDS: Vasculitis; necrotizing glomerulonephritis; antineutrophil cytoplasm autoantibody;
kidney biopsy; end-stage renal disease (ESRD).i
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pegener granulomatosis and microscopic
polyangiitis are antineutrophil cytoplas-
ic antibody (ANCA)-associated small-vessel vas-
ulitides that cause rapidly progressive pauci-
mmune necrotizing glomerulonephritis.1 The
outine use of immunosuppressive therapies has
ramatically improved prognosis,2,3 and random-
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American Journal of Kid50zed trials have established evidence-based treat-
ent.4,5 Nevertheless, significant morbidity and
ortality are still prevalent as a result of both
isease and treatment, particularly in the elderly.6
Previous reports have correlated presenting
erum creatinine level with kidney outcome in
atients with pauci-immune necrotizing glomer-
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Outcomes in Pauci-immune Necrotizing GN 251lonephritis;7,8 however, at least some patients
ith severe kidney disease recover independent
idney function when treated appropriately.5
hereas the primary purpose of a kidney biopsy
s diagnostic, it not infrequently reveals a combi-
ation of acute and chronic lesions that may have
rognostic relevance. A number of studies have
ighlighted the value of measurements of glomer-
lar morphologic characteristics in this context;
owever, assessments of tubular and interstitial
amage frequently are semiquantitative and may
e subject to greater variability. Moreover, assess-
ents that involve many components are not
ecessarily readily applicable in routine practice
utside of specialist centers.7,9
We have previously described a simple mor-
hometric measure of chronic damage that as-
esses the entire area of renal cortex in a biopsy
pecimen and have shown that the index predicts
idney survival in various settings.10-12 We hy-
othesized that the index would predict kidney
urvival in patients with pauci-immune necrotiz-
ng glomerulonephritis and, in this study, set out
o test its performance in comparison to quantita-
ive measurements of glomerular morphologic
haracteristics in a retrospective cohort of 390
atients sampled at a single center.
METHODS
linical Data
All patients at the Queen Elizabeth Hospital, Birming-
am, UK, with a diagnosis of pauci-immune necrotizing
lomerulonephritis by kidney biopsy between 1983 and
002 were included. Clinical data were obtained from pa-
ient records (hospital and general practice). Date and cause
f death were obtained from public records and death
ertificates. Serum creatinine was measured at the time of
iopsy or before the initiation of acute dialysis therapy if this
ccurred before the biopsy was performed. Biopsies ordi-
arily were performed before administration of immunosup-
ressive therapy or shortly thereafter in exceptional cases.
epeated biopsies ordinarily were performed before escala-
ion of immunosuppression. Patients were defined as reach-
ng the end point of end-stage renal disease (ESRD) when
hey required permanent renal replacement therapy, in other
ords, long-term dialysis therapy or transplant. Patients
ho required acute dialysis at presentation or relapse, but
ho recovered independent kidney function after treatment,
ere not classified as reaching the end point. Time to the end
oint was defined as time elapsed between biopsy (time
ero) and either death or initiation of permanent renal
eplacement therapy. The status of all patients was deter-
ined at the end of 2004. Research was conducted inccordance with the Declaration of Helsinki. 0During the period studied, standard treatments used were
yclophosphamide (either pulsed intravenous or daily oral)
or active disease with high-dose prednisolone (1 mg/kg)
apered over 2-3 months. On remission and after 3 to 6
onths of treatment, patients were switched to maintenance
herapy with azathioprine and low-dose prednisolone. Few
atients stopped the medication. Those with either dialysis-
equiring acute kidney failure or pulmonary hemorrhage
ere treated using plasma exchange.
Death certificates were available for 186 of 214 patients
ho died. Forty-three patients died within 3 months of
iagnosis, and certified causes of death in these cases were
idney failure, vasculitis, or infection. We classified all
eaths during this period as related to active vasculitis
ecause infection was presumed to be secondary to intensive
mmunosuppression. Deaths attributed to infection  3
onths after diagnosis were coded separately.
easurement of Indexof ChronicDamageandOther
athologic Investigations
Stored slides of renal biopsy specimens were examined
etrospectively without knowledge of patient details and
rrespective of the number of glomeruli in the specimen. On
representative section, usually stained using periodic acid–
ethenamine silver, the total number of glomeruli was
ounted. Each glomerulus was put into 1 of 5 categories,
hich were summed for each biopsy and expressed as
ercentages of the total number of glomeruli: normal glo-
eruli, globally sclerosed glomeruli, glomeruli with isch-
mic shrinkage, glomeruli with active vasculitic lesions, and
lomeruli with healed vasculitic lesions. Active vasculitic
esions were defined as segmental or global areas of combi-
ations of thrombosis, disruption of capillary basement
embranes, and cells in Bowman space. Healed vasculitic
esions were defined as those in which areas of fibrosis
ncluded the glomerular tuft and Bowman space. Active and
ealed segmental lesions usually were sharply demarcated
rom the rest of the glomerulus. Lesions that were healing
ere arbitrarily assigned to active or healed categories based
n the relative amounts of cells and fibers in the lesions.
rteritis or arteriolitis was diagnosed by the finding of
brinoid necrosis and/or an inflammatory infiltrate in the
all of relevant vessels.
The index of chronic damage was measured in each
iopsy specimen as previously described.10-12 Briefly, using
digital image of renal cortex, atrophic areas were outlined
y freehand and their cross-sectional areas were measured in
ixels. Atrophic areas were defined as those containing any
ombination of globally sclerosed glomeruli, shrunken tu-
ules with thickened basement membranes, interstitial fibro-
is, cysts, and occluded vessels. The cortex in the image then
as outlined and its area was measured. This was repeated
ntil all cortex was measured. The total of atrophic areas was
xpressed as a percentage of total cortical area and called the
ndex of chronic damage. This could range from 0% in a
idney without no chronic damage to 100% in a completely
trophic kidney.
Previously, the limits of interobserver agreement for the
ndex of chronic damage were determined to be between
.88 (95% confidence interval [CI], 0.82-0.93) and 1.22
(
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Day et al25295% CI, 1.15-1.30), with a mean agreement of 1.03 (95%
I, 0.99-1.07).11 The limits of intraobserver agreement were
.79 (95% CI, 0.74-0.85) and 1.29 (95% CI, 1.20-1.39), with
mean of 1.01 (95% CI, 0.97-1.06).11 The definition of the
ndex of chronic damage is listed in Box 1.
ataAnalysis
Analysis was performed using SPSS for Windows, ver-
ion 14 (SPSS Inc, www.spss.com/uk/). Univariable and
ultivariable survival analyses were performed initially
sing stepwise Cox regression with creatinine level as a
ontinuous variable. Histologic parameters were divided
nto groups of 1 standard deviation to make hazard ratios
ore meaningful. When 1 biopsy was performed, only the
nitial presenting biopsy specimen was used in these analy-
es. Time origin (t 0) was the value of the parameter at the
nitial presenting biopsy. If a patient did not progress to
SRD, they were censored at either death or last follow-up,
ith the latter at least 2 years after the initial presentation.
orrelations of pathologic variables with serum creatinine
oncentrations at biopsy or ANCA status were computed
sing Spearman rank correlation for nonparametric vari-
bles. The C statistic is the proportion of pairs of individuals
or which the model correctly predicted which individual
ad the shorter time to event (pairs for which this is not
nown were excluded from the calculation).
In analysis of the repeated biopsy data, when there were 2
iopsies available, only the earliest and most recent were
nalyzed. Patients underwent a repeated biopsy because
f either a suspected disease flare or inadequate response
o therapy. As such, this group is subject to selection bias.
ates of changes in the index of chronic damage, percent-
ge of normal glomeruli, and serum creatinine concentra-
ion were calculated by dividing the change in each
arameter between the 2 biopsies by the time separating
he 2 samples.
Further analysis of the initial biopsy data was performed
y dividing the population into quartiles of percentage of
Box 1. Definition and Measurement of Index of
Chronic Damage
Definition of the index of chronic damage
Percentage of renal cortex comprising atrophic areas
defined as any combination of global glomerular sclero-
sis (but not segmental sclerosis), tubular atrophy
(shrunken tubules with thickened basement mem-
branes), interstitial fibrosis, cysts, and completely oc-
cluded vessels.
Measurement of index of chronic damage
A digital image is obtained of 1 routinely prepared
2-m section of the renal biopsy stained using periodic
acid–methenamine silver. Using image analysis soft-
ware, the entire renal cortex (area inside the renal
capsule and outside the medulla) is outlined by freehand.
Cortical area is measured in arbitrary units. Areas of
chronic damage are outlined by freehand, and their total
area is measured and expressed as a percentage of
cortical area.ormal glomeruli. Quartile division was not possible for the mndex of chronic damage because a large number of biopsy
pecimens showed an index of 0%. Therefore, this parame-
er was divided into 4 groups: all biopsy specimens with an
ndex of 0% and the remainder of the population divided into
ertiles. Differences between groups in progression to ESRD
ere calculated using stepwise Cox regression. A likelihood
atio comparing goodness of fit was used to test for interac-
ions between creatinine level and 2 histologic variables
percentage of normal glomeruli and index of chronic dam-
ge) in multivariable analysis of the entire population.
RESULTS
aselineCharacteristics andOverall Outcomes
During the study period, 390 patients were
iven a diagnosis of pauci-immune necrotizing
lomerulonephritis. Of these, 90 patients under-
ent 1 kidney biopsy, but only initial biopsies
ere included in the analysis unless otherwise
tated (see Repeated Biopsy Data in this section).
edian age at initial biopsy was 64 years (range,
5-90 years), and median serum creatinine level
t biopsy was 3.86 mg/dL (range, 0.52-20.6
g/dL). Follow-up was until patient death or for
t least 2 years from the initial biopsy for surviv-
ng patients, with median follow-up of 166 weeks
range, 1 day-1,256 weeks). During follow-up,
14 (55%) patients died: 89 (23%) during the
rst year, 149 (40%) by 5 years, and 184 (49%)
y 10 years. Permanent renal replacement therapy
as required in 87 (22%) patients: 54 (14%) in
he first year, 67 (18%) by 5 years, and 76 (21%)
y 10 years.
In the present cohort, the median index of
hronic damage was 10% (range, 0%-94%). Base-
ine characteristics and outcomes for patients
egregated by index of chronic damage values
re listed in Table 1. Median percentage of normal
lomeruli was 31% (range, 0%-100%), and median
ercentage of glomeruli with active lesions was
9% (range, 0%-100%). ANCA immunofluores-
ence data were available for 230 patients. Pe-
inuclear ANCA (pANCA)-positive patients were
ignificantly older at presentation than cytoplasmic
NCA (cANCA) patients (median age, 67 vs 57
ears; P  0.001). The mean index of chronic
amage was significantly higher in pANCA-posi-
ive patients (31.17% vs 19.55%; P  0.003),
hich remained significant after correction for age
P 0.04). Furthermore, pANCA-positive patients
ad a higher percentage of globally sclerosed glo-
eruli (P  0.001), whereas cANCA-positive pa-
t
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Outcomes in Pauci-immune Necrotizing GN 253ients showed more glomeruli with active lesions
P 0.001) and arteritis (P 0.03).
ortality
Death was predicted by serum creatinine level
t biopsy (hazard ratio, 1.12; 95% CI, 1.09-1.16;
 0.001) and age (hazard ratio, 1.05; 95% CI,
.04-1.07; P  0.001), but not by any histologic
ariable examined. An association between
ANCA versus cANCA positivity and increased
ortality (P  0.03) was not significant after
orrection for age.
Only 2 patients died of active vasculitis  3
onths after diagnosis. During the entire study
eriod, major causes of death were as follows:
ctive vasculitis or complications of therapy within
months of diagnosis, 45 (24%); ischemic heart
isease or stroke, 42 (23%); infection 3 months
rom diagnosis, 41 (22%); chronic kidney dis-
ase, 32 (17%); malignancy 20 (11%); and gas-
rointestinal disease, 6 (3%).
Using data obtained from the UK Office of
ational Statistics for age-standardized death
ates per 1,000 population in 2002, the calculated
tandardized mortality ratio for this patient co-
ort was 4.74 (95% CI, 3.62-6.32) with an odds
atio of 9.32 (95% CI, 6.45-13.47).
orrelationof VariablesWith SerumCreatinine
oncentration at Biopsy
There were significant correlations between se-
um creatinine level at biopsy and age (r 0.273;
 0.001), index of chronic damage (r  0.263;
 0.001), percentage of normal glomeruli (r 
0.583; P 0.001), percentage of glomeruli with
ctive lesions (r 0.368; P 0.001), and percent-
ge of globally sclerosed glomeruli (r  0.192;
 0.001). There was no correlation between
erum creatinine level at biopsy and either ANCA
ubtype (r  0.033; P  0.6) or presence of
rteritis (r0.51; P 0.4).
rogression to ESRD
Using univariable analysis, serum creatinine level
t biopsy and all histologic variables examined
ignificantly correlated with ESRD both at 1 year
nd throughout the duration of the study. In con-
rast, age was not associated with ESRD (Table 2).
n multivariable analysis, serum creatinine level atbiopsy and percentage of normal glomeruli were1( 2(
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Day et al254ndependent predictors of ESRD (Table 3). This
as reflected in C statistics for Cox regression:
 0.8 for creatinine level alone and C 0.83 for
reatinine level with percentage of normal glo-
eruli. No significant interaction was shown be-
ween serum creatinine level and either percentage
f normal glomeruli or index of chronic damage.
onsidering those for whom ANCA immunofluo-
escence was known, there was no difference in
rogression to ESRD between pANCA- and
ANCA-positive patients (P 0.9).
Dividing the index of chronic damage into
roups suggested a threshold effect because kid-
ey outcome did not differ significantly for the
rst 3 groups. However, the fourth group (48%
hronic damage) had a significantly worse kid-
ey outcome (Table 1). A threshold effect also
as apparent for normal glomeruli because pro-
ression to ESRD did not differ significantly for
he third (32%-65%) compared with the fourth
uartile (66%), whereas progression to ESRD
as significantly more frequent for the first (0%-
%) and second (9%-31%) quartiles (ie, biopsy
pecimens showing the least normal glomeruli;
Table 3. Multivariable An
ESRD at 1
HR 95% CI
Cr at presentation (mg/dL) 1.21 1.14-1.28
Normal glomeruli 0.42 0.21-0.82
Note: Multivariable analyses were performed using forw
hronic damage; percentages of normal, active, and sclero
resentation (milligrams per deciliter).
Table 2. Univariable An
ESRD a
HR 95%
ge (/1 SD) 1.32 0.97-1
nitial SCr (/1 mg/dL) 1.26 1.19-1
Normal glomeruli (/1 SD) 0.27 0.15-0
Active glomeruli (/1 SD) 1.59 1.24-2
Sclerosed glomeruli (/1 SD) 1.46 1.13-1
ndex of chronic damage (/1 SD) 1.72 1.32-2
Note: SCr is treated as a continuous variable; other var
ears for age, 33% for percentage of normal glomeruli, 3
clerosed glomeruli, and 30% for index of chronic damage.
Abbreviations: CI, confidence interval; ESRD, end-stag
tandard deviation.Abbreviations: CI, confidence interval; ESRD, end-stage renal dable 4). Conversely, the second, third, and fourth
uartiles of normal glomeruli had better kidney
utcomes than the first quartile (8%; not shown).
epeatedBiopsyData
Data confirm that histologic variables mea-
ured in a first biopsy specimen are associated
ith ESRD across the entire patient cohort. In
his study, 90 patients underwent  1 biopsy,
roviding an opportunity to examine the associa-
ion of changes in histologic variables with out-
omes of individual patients. Median time be-
ween biopsies was 397 days (range, 9-6,666
ays). Comparing patients in the subgroup that
eveloped ESRD (n  40) with those who did
ot (n  50), second biopsy specimens from
hose reaching ESRD showed a higher median
ndex of chronic damage (66.5% vs 29.0%) and
ecreased median percentage of normal glo-
eruli (6.0% vs 20.0%). In multivariable analy-
is, only creatinine level at the second biopsy
median, 7.52 mg/dL in patients developing
SRD vs 2.59 mg/dL in those retaining indepen-
ent kidney function) and rate of change in index
of Progression to ESRD
ESRD During Total Follow-up
P HR 95% CI P
0.001 1.19 1.13-1.25 0.001
0.01 0.47 0.31-0.71 0.001
pwise Cox regression. Variables used were age; index of
meruli (all divided by standard deviation); and SCr level at
of Progression to ESRD
r ESRD During Total Follow-up
P HR 95% CI P
0.07 1.15 0.92-1.45 0.2
0.001 1.24 1.18-1.29 0.001
0.001 0.34 0.23-0.49 0.001
0.001 1.47 1.20-1.82 0.001
0.003 1.54 1.27-1.87 0.001
0.001 1.78 1.42-2.22 0.001
re divided into groups by 1 SD, which corresponds to 16
r percentage of active glomeruli, 21% for percentage of
l disease; HR, hazard ratio; SCr, serum creatinine; SD,alyses
Year
ard ste
sed gloalyses
t 1 Yea
CI
.78
.33
.49
.07
.88
.24
iables a
0% fo
e renaisease; HR, hazard ratio; SCr, serum creatinine.
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Outcomes in Pauci-immune Necrotizing GN 255f chronic damage (0.11%/d vs 0.009%/d) were
ssociated with progression to ESRD (Table 5).
or the entire subgroup, median rate of change in
he index of chronic damage was 10.76%/y
Fig 1).
DISCUSSION
The prognosis for patients with pauci-immune
ecrotizing glomerulonephritis has improved with
herapeutic immunosuppression.2,3 Nonetheless,
y 5 years, 18% of patients in this cohort re-
uired permanent renal replacement therapy and
0% had died. Previous studies also have re-
orted high mortality in patients with systemic
asculitis.21,23 Allowing for the limitations of
ccuracy in death certification, the high rate of
nfection-related mortality in this study supports
he hypothesis that adverse effects of therapy
ontribute to poor outcome and emphasizes the
dvantage of identifying patients with salvage-
ble kidney function.
Table 4. Progression to End-Stage Renal Dise
Percentage of Normal
Glomeruli in Quartile
Quartile Range Median %
1 0-8 0 46.6
2 9-31 17 22.8
3 32-65 46 14.1
4 67-100 86.5 7.5
Note: Global P 0.001.
Table 5. Univariable and Multivariable Analyses of Progr
Ren
erum creatinine at biopsy 1 (/1 mg/dL)
erum creatinine at biopsy 2 (/1 mg/dL)
ndex of chronic damage at biopsy 1 (/1 SD)
ndex of chronic damage at biopsy 2 (/1 SD)
ercentage of normal glomeruli at biopsy 1 (/1 SD)
ercentage of normal glomeruli at biopsy 2 (/1 SD)
ate of change in serum creatinine (mg/dL/d) (/1 SD)
ate of change in index of chronic damage (%/d) (/1 SD)
ate of change in percentage of normal glomeruli (%/d) (/1
Note: All variables were used in multivariable stepwise C
Abbreviation: SD, standard deviation.Previous smaller studies have reported more
ong-term damage in pANCA/myeloperoxidase-
NCA–positive versus cANCA/proteinase
–ANCA patients, but similar outcomes.9,19-22
ur study supports this concept and indicates
hat ANCA subtype should not influence treat-
ent. The basis of the difference in pathologic
eatures between the 2 subgroups is uncertain
nd could reflect either earlier diagnosis in
atients with cANCA (perhaps because of promi-
ent extrarenal symptoms) or genuinely diver-
ent disease characteristics.
Other studies of kidney biopsies in patients
ith systemic vasculitis (Table 6) have involved
elatively complex scoring systems.7,9,17,22,25,26
oreover, the consistency of biopsy interpreta-
ion in patients with pauci-immune necrotizing
lomerulonephritis is uncertain because al-
hough quantitative measurements of glomeru-
ar morphologic characteristics show satisfac-
ory agreement, interobserver agreement for
Quartiles of Percentage of Normal Glomeruli
Progression to End-Stage Renal Disease
P Relative Risk (95% confidence interval)
0.001 10.53 (4.71-23.54)
0.001 4.39 (1.86-10.40)
0.1 1.99 (0.80-5.01)
— 1.00 (reference)
to End-Stage Renal Disease in Patients Undergoing  1
sy
Univariable Analysis Multivariable Analysis
Hazard Ratio
(95% confidence
interval) P
Hazard Ratio
(95% confidence
interval) P
1.16 (1.08-1.25) 0.001
1.44 (1.29-1.61) 0.001 1.42 (1.26-1.60) 0.001
1.35 (0.89-2.04) 0.2
2.45 (1.73-3.61) 0.001
0.42 (0.26-0.69) 0.001
0.48 (0.25-0.93) 0.03
0.94 (0.85-1.03) 0.2
3.51 (1.92-6.42) 0.001 2.08 (1.11-3.89) 0.02
1.47 (0.80-2.86) 0.2
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Day et al256ichotomous variables used to score tubuloin-
erstitial damage appears to be poor.13 Simi-
arly, the reproducibility and predictive value
f semiquantitative chronicity scores in pa-
ients with lupus nephritis is controversial, and
heir applicability outside specialist referral
enters is disputed.14,15 More recently, com-
uter-assisted morphometric assessment of lu-
us nephritis has been described and has pre-
icted outcome in a relatively small cohort
n  48).16
Our study comprises a large cohort with a
nified diagnosis and extended follow-up. Se-
um creatinine level at biopsy correlated with
lomerular morphologic characteristics, as pre-
iously reported,7,8 and with index of chronic
amage. Furthermore, both glomerular morpho-
ogic characteristics and the index of chronic
amage significantly correlated with kidney
utcome. Multivariable analysis showed se-
um creatinine level at biopsy and percentage
f normal glomeruli in the initial biopsy speci-
en to be independent predictors of ESRD. As
n other studies, no pathologic features pre-
icted death, which was predicted by age and
erum creatinine level at biopsy.
In a subgroup of patients undergoing re-
eated biopsy (performed in the context of
Figure 1. Progression to end-stage renal failure (ESRF)
tratified by rate of decrease in index of chronic damage
etween the first and last renal biopsy specimens (P 
.001). Values below the plot indicate numbers remaining
n the analysis at each time.uspected disease flare or inadequate response no therapy), accelerated change in the index of
hronic damage was associated independently
ith kidney outcome, whereas percentage of
ormal glomeruli was not. Previous studies
sing repeated biopsy data have shown progres-
ion of chronic damage (semiquantitatively
cored)17 or an increase in global glomerulo-
clerosis,18 but not an association with progres-
ion to ESRD. The index of chronic damage
ight provide additional information because
t reflects irreversible damage in the tubulo-
nterstitial and vascular compartments, as well
s glomerular scarring. Furthermore, the index
ay be more meaningful when a biopsy speci-
en contains only a few glomeruli. We have
lready reported that the index is an indicator
f progression to ESRD in patients with lupus
ephritis11 and in a heterogeneous cohort of
atients with chronic kidney disease10 (pre-
ominantly immunoglobulin A nephropathy and
enoch-Schönlein nephritis).
There are several limitations to our study. It
as a retrospective analysis with uncontrolled
ifferences between patient groups, mainly in
reatment regimens. ANCA specificity was an-
lyzed using indirect immunofluorescence
ather than enzyme-linked immunosorbent as-
ay and was recorded in only 59% (230/390) of
atients, reflecting the available data set, rather
han an unusually high proportion of truly
NCA-negative cases. In addition, there has
een only limited assessment of the extent of
nter- and intraobserver agreement using the
ndex of chronic damage. Previous studies
nvolving a small number of pathologists have
hown that the degree of variation is low,10 but
his merits confirmation. Furthermore, re-
eated biopsy analyses could be affected by
election bias.
Although histologic variables can correlate
ith or predict kidney outcome, histology has
ot yet been used to direct treatment in a trial
etting. An analysis of biopsies from the
EPEX (methyl prednisolone or plasma ex-
hange for severe renal vasculitis) trial con-
luded that for patients receiving plasma ex-
hange, the chance of kidney recovery always
xceeds the risk of therapy-related death regard-
ess of the severity or nature of histopathologic
hange.24 This suggests that treatment should
ot be restricted for patients who present with
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Outcomes in Pauci-immune Necrotizing GN 257everely decreased kidney function. Neverthe-
ess, the likelihood of reaching ESRD or dying
s substantial using any current treatment, and
eath from complications of therapy is well
ecognized. Accordingly, the search for robust
ools that could support treatment decisions
either limitation when it is futile or intensifi-
ation when the risk of inadequate response is
reater) remains relevant.
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asarod et al17
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Wagener
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eumann et al9
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67 SCr;
ne
ch
sys
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e Lind van Wijngaarden
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500 mol/L at entry)
100/1 y GFR
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